NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

They did not apply for EAMs because it was a crap program just like the U.S. current early access program. It put the burden on the companies to supply the drug at their actual minimal cost, which would not recoup scaling up a factory, hiring people, getting a commercial license and basically operating as if they were a commercial entity. That was a non-starter not just for NWBO, but if you peruse the companies that went through the hurdle of the initial designations, you’ll see that it required regular renewal and most did not bother. The EAMS program basically was a failure, hence the U.K. Specials program as a regulator driven work around basically.